Pharmaceutical News

RSS

BNT162b2 COVID vaccine stimulates significant antibody response in lung cancer patients

In a recent article posted to the medRxiv* preprint server, scientists from Japan assessed the safety and immunogenicity of coronavirus disease 2019 (COVID-19) BNT162b2 vaccine among lung cancer patients under treatment.

28 Jun 2022

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) SP1-77 that broadly neutralized its multiple variants of concern (VOCs).

28 Jun 2022

Researchers assess the evidence basis for medications used to treat spine-related pain in older adults

Spine-related pain is increasingly common in older adults. While medications play an important role in pain management, their use has limitations in geriatric patients due to reduced liver and kidney function, comorbid medical problems and polypharmacy (the simultaneous use of multiple drugs to treat medical conditions).

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

A recent study posted to the bioRxiv* preprint server assessed whether niclosamide could be employed in coronavirus disease 2019 (COVID-19) therapy.

28 Jun 2022

3rd COVID vaccine significantly reduced hospitalizations and deaths during Australia's 1st Omicron wave

Researchers compare vaccine effectiveness in people who received three doses of the COVID-19 vaccine as compared to those who received two doses.

27 Jun 2022

Vitamin D supplements show promise to counter the adverse effects of diabetes drug on bone health

Vitamin D supplementation may help offset damaging bone loss that occurs in some people who take canagliflozin, a commonly prescribed diabetes drug.

27 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

24 Jun 2022

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

There remains no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, state the authors of an updated Cochrane Review, which now contains 11 trials across 3409 people.

24 Jun 2022

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

In a recent article posted to the medRxiv* preprint server, investigators in the United States illustrated that rebound of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can occur in some patients following molnupiravir and Paxlovid SARS-CoV-2 therapy.

23 Jun 2022

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

23 Jun 2022

Paxlovid is shown to be effective in treating COVID-19

In a recent Morbidity and Mortality Weekly Report (MMWR) published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers described cases of coronavirus disease 2019 (COVID-19)–related hospitalizations and emergency department (ED) visits in five to 15 days following Paxlovid (Nirmatrelvir/ritonavir ) treatment.

22 Jun 2022

INTEGRA’s PIPETBOY acu 2 pipette controller takes a deep dive into cellular physics

...

From INTEGRA Biosciences 22 Jun 2022

New pain medications with high abuse potential more likely to be successfully developed

Despite the prevalence and societal costs of pain in the United States, investment in pain medication development is low, due in part to poor understanding of the probability of successful development of such medications

21 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Researchers evaluated the efficacy of PHELA, a traditional African drug, against SARS-CoV-2 in vitro.

21 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

In a recent study published in the journal Nature Medicine, researchers assessed the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against symptomatic infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs) by genetic mismatch/distance (GD) analysis.

20 Jun 2022

How effective are mRNA COVID-19 vaccine boosters against Omicron?

In a recent study posted to the medRxiv* preprint server, researchers University of Washington, University of Michigan, Duke University, and Veterans Affairs Portland Healthcare System assessed the effectiveness of the coronavirus disease 2019 (COVID-19) booster vaccines.

19 Jun 2022

Previous
1
...
94
95
96
97
98
99
100
...
1453
Next

Pharmaceutical News

BNT162b2 COVID vaccine stimulates significant antibody response in lung cancer patients

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

Researchers assess the evidence basis for medications used to treat spine-related pain in older adults

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

3rd COVID vaccine significantly reduced hospitalizations and deaths during Australia's 1st Omicron wave

Vitamin D supplements show promise to counter the adverse effects of diabetes drug on bone health

Bisphosphonates appear to improve COVID-19 exposure outcomes

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

Paxlovid is shown to be effective in treating COVID-19

INTEGRA’s PIPETBOY acu 2 pipette controller takes a deep dive into cellular physics

New pain medications with high abuse potential more likely to be successfully developed

Insufficient drug exposure most likely to cause COVID-19 rebound

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Real-world study shows Paxlovid associated with lower hospitalization rates

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

How effective are mRNA COVID-19 vaccine boosters against Omicron?

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News